Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EPS (Basic) (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed EPS (Basic) for 11 consecutive years, with -$3.28 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) changed N/A to -$3.28 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.66 through Dec 2025, changed N/A year-over-year, with the annual reading at -$5.59 for FY2025, 846.84% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$3.28 at Crescent Biopharma, down from -$1.77 in the prior quarter.
  • The five-year high for EPS (Basic) was -$0.04 in Q1 2025, with the low at -$3.28 in Q4 2025.
  • Average EPS (Basic) over 5 years is -$0.52, with a median of -$0.19 recorded in 2022.
  • Peak annual rise in EPS (Basic) hit 76.47% in 2025, while the deepest fall reached 1080.83% in 2025.
  • Over 5 years, EPS (Basic) stood at -$0.33 in 2021, then skyrocketed by 42.42% to -$0.19 in 2022, then increased by 26.32% to -$0.14 in 2023, then decreased by 7.14% to -$0.15 in 2024, then plummeted by 2086.93% to -$3.28 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$3.28, -$1.77, and -$1.57 for Q4 2025, Q3 2025, and Q2 2025 respectively.